Orphan drug status for KNBA101, TLF Oral Solution

KBPA101 for pseudomonas pneumonia
On October 3, 2006, the U.S. Food and Drug Administration (FDA) approved orphan drug status for a human antibody called KBPA101, made by Kenta Biotech, Ltd., for the treatment of hospital-acquired pneumonia caused by the bacteria Pseudomonas aeruginosa. This type of pneumonia may be life-threatening for patients on respirators. Also, this particular bacteria often resists antibiotic treatment, so having a different type of drug to attack it could be very helpful. KBPA101 was granted orphan drug designation from the European Medicines Agency (EMEA) in July 2006.

TLF Oral Solution for kidney cancer
On October 12, 2006, the FDA approved orphan drug status for an oral form of talactoferrin alfa called TLF Oral Solution, made by Agennix, Inc., for treating a form of kidney cancer called renal cell carcinoma. Taking oral TLF stimulates the body's immune system to attack the cancer cells. In clinical trials the drug caused kidney tumors to shrink or stop growing as fast.